Elabscience

Recombinant Human SerpinE1/PAI-1 Protein (His Tag)(Active)

Product Code:
 
PKSH031702
Product Group:
 
Recombinant Proteins
Supplier:
 
Elabscience
Host Type:
 
Human
Regulatory Status:
 
RUO
Shipping:
 
This product is provided as lyophilized powder which is shipped with ice packs.
Storage:
 
Samples are stable for up to twelve months from date of receipt at -70°C. Store it under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
PKSH031702-50ug50ug£773.00
Quantity:
PKSH031702-1mg1mg£5,378.00
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: China.
Typical lead time: 14-21 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • Show All

Further Information

Abbreviation:
SerpinE1;PAI-1
Accession:
NP_000593.1
Activity:
Measured by its ability to inhibit uPA cleavage of a peptide substrate, N-carbobenzyloxy-Gly-Gly-Arg-7-amido-4-methylcoumarin (Z-GGR-AMC). The IC50 value is < 60 nM.
Background:
Plasminogen activator inhibitor 1, also known as PAI-1, Endothelial plasminogen activator inhibitor, SerpinE1 and PLANH1, is a secreted glycoprotein which belongs to the serpin family. SerpinE1 is the primary physiological inhibitor of the two plasminogen activators urokinase (uPA) and tissue plasminogen activator (tPA). Its rapid interaction with TPA may function as a major control point in the regulation of fibrinolysis. Defects in SerpinE1 are the cause of plasminogen activator inhibitor-1 deficiency (PAI-1 deficiency) which is characterized by abnormal bleeding due to SerpinE1 defect in the plasma. High concentrations of SerpinE1 have been associated with thrombophilia which is an autosomal dominant disorder in which affected individuals are prone to develop serious spontaneous thrombosis. Studies of PAI-1 have contributed significantly to the elucidation of the protease inhibitory mechanism of serpins, which is based on a metastable native state becoming stabilised by insertion of the RCL into the central beta-sheet A and formation of covalent complexes with target proteases. Greater expression of PAI-1 has been associated with increased survival of cells and resistance to apoptosis. PAI-1 appears to influence apoptosis by decreasing cell adhesion (anoikis) as well as its effect on intracellular signaling.
Calculated MW:
44.2 kDa
Endotoxin:
< 1.0 EU per ug of the protein as determined by the LAL method.
Expression Host:
HEK293 Cells
Formulation:
Lyophilized from sterile 50mM NaAc, 0.1M NaCl, pH 5.5
Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the printed manual.
Fusion tag:
C-His
ObservedMW:
45 kDa
Purity:
> 97 % as determined by reducing SDS-PAGE.
Sequence:
Met 1-Pro 402
Target Synonym:
Plasminogen Activator Inhibitor 1;PAI;PAI-1;Endothelial Plasminogen Activator Inhibitor;Serpin E1;SERPINE1;PAI1;PLANH1;SERPINE1

Documents